Corrigendum to 'Health-related quality of life in patients with advanced well-differentiated pancreatic and extrapancreatic neuroendocrine tumors treated with surufatinib versus placebo: Results from two randomized, double-blind, phase III trials (SANET-p and SANET-ep)' [European Journal of Cancer 169 (2022) 1-9]

Eur J Cancer. 2023 Jan:178:247-248. doi: 10.1016/j.ejca.2022.10.001. Epub 2022 Nov 16.
No abstract available

Publication types

  • Published Erratum